XTAE
MTLF
Market cap25mUSD
Oct 09, Last price
249.90ILS
1D
2.42%
1Q
-4.62%
IPO
-60.78%
Name
Matricelf Ltd
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
1.83%
Rev. gr., 5y
%
Revenues
0
Net income
-28m
L+178,445.76%
CFO
-15m
L+124,836.19%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Matricelf Ltd, a biotechnology company, develops a platform for autologous tissue engineering for various medical conditions. The company’s regenerative medicine platform intends to cure a range of medical conditions, including spinal cord injuries, age-related macular degeneration, Parkinson’s disease, and myocardial infarction, as well as for 3D bioprinting. The company has a strategic collaboration with Sheba Medical Center for the development and clinical advancement of its neural tissue implant product for the treatment of spinal cord injury. The company has a strategic collaboration with CiRA Foundation for the development of regenerative manufacturing technologies and the evaluation of iPSC-based neural tissue engineering for therapeutic applications. The company was incorporated in 2019 and is based in Ness Ziona, Israel.
Key people
Sigal Rousseau
Chief Financial Officer · since 2021
Tal Dvir
Chief Scientific Officer, Director · since 2019
Sinai Alon
Vice President - Operations · since 2021
Asaf Toker
Chief Executive Officer, General Manager · since 2019
Chinese Oak
Deputy General Director, Director · since 2019
Tal Ben Naria
Operations Manager · since 2020
Doron Birger
Chairman of the Board · since 2020
Ruth Arnon
Independent Director · since 2021
Uri Hershkovich
Independent Director · since 2021
Valuation
Title ILS in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||